行情

CELG-RT

CELG-RT

Celgene
NYSE

实时行情|Nasdaq Last Sale

0.2083
+0.0007
+0.36%
休市 16:00 09/24 EDT
开盘
0.2000
昨收
0.2076
最高
0.2300
最低
0.2081
成交量
9,189
成交额
--
52周最高
0.4700
52周最低
0.1800
市值
1.48亿
市盈率(TTM)
0.0260
分时
5日
1月
3月
1年
5年
用于美国 IPO 的 Brief-Exscientia 文件
reuters.com · 09/10 15:56
美国FDA批准百时美施贵宝的多发性骨髓瘤治疗
reuters.com · 03/27 04:47
安进第二季度营收增长6％，股价下降2％
Amgen Inc said on Tuesday second-quarter revenue rose 6% as higher sales of newer drugs, including recently added psoriasis treatment Otezla, offset declining sales of older medicines which were due in some cases to people staying home to avoid exposure to...
Reuters · 2020/07/28 22:37
由于信心下降，美国银团贷款发行量暴跌
Trade wars, uncertainty about Brexit and a potential looming recession reduced US syndicated lending to US$2.11trn, an abysmal 20% drop from the prior record-year tally.
Reuters · 2020/01/03 17:57
US syndicated loan issuance tumbles as confidence drops
Trade wars, uncertainty about Brexit and a potential looming recession reduced US syndicated lending to US$2.11trn, an abysmal 20% drop from the prior record-year tally.
Reuters · 2020/01/03 17:57
2019年投资级市场流动性，稳定和低迷
Issuance in the investment grade loan market was strong this year, though slightly down from 2018, supported by jumbo merger and acquisition (M&A) transactions, as the market proved its capacity to continue to fund big-ticket companies.
Reuters · 2019/12/19 17:26
Investment grade market was liquid, stable and muted in 2019
Issuance in the investment grade loan market was strong this year, though slightly down from 2018, supported by jumbo merger and acquisition (M&A) transactions, as the market proved its capacity to continue to fund big-ticket companies.
Reuters · 2019/12/19 17:26
百时美施贵宝报告通过Celgene交易获得的癌症治疗的积极数据
Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial.
Reuters · 2019/12/07 19:04
更多
财务预测
暂无数据
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解CELG-RT最新的财务预测，通过CELG-RT每股收益，每股净资产，每股现金流等数据分析Celgene近期的经营情况，然后做出明智的投资选择。
暂无数据
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.45%
制药与医学研究
-1.02%
高管信息
Chairman/Chief Executive Officer/Director
Mark Alles
Executive Vice President
Peter Kellogg
Corporate Executive
Terrie Curran
Corporate Executive
Rupert Vessey
Corporate Executive
Michael Pehl
Executive Vice President/General Counsel
Jonathan Biller
Chief Financial Officer/Executive Vice President
David Elkins
Executive Vice President/General Counsel/Secretary
Gerald Masoudi
Lead Director
Michael Casey
Director
Hans Bishop
Director
Julia Haller
Independent Director
Richard Barker
Independent Director
Michael Bonney
Director
Patricia Hall
公告日期
每股分红
除权日期
--
每股分红:USD 6.932592
2013/10/08
  • 全部
  • 财务报告
  • 内部人交易
更多
CELG-RT 简况
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

微牛提供Celgene Corporation(NYSE-CELG RT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CELG RT股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CELG-RT股票基本功能。